## Correction



Correction: Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy

## The PLOS ONE Staff

There are several errors in the published article. The authors are listed out of order. Please view the correct author order, affiliations, and citation here:

Zhen-Yu Zhang<sup>1</sup>, Jian Xu<sup>1</sup>, Yong Ren<sup>2</sup>, Kay Ka-Wai Li<sup>3</sup>, Ho-Keung Ng<sup>3</sup>, Ying Mao<sup>1</sup>, Ping Zhong<sup>1\*</sup>, Yu Yao<sup>1\*</sup>, Liang-Fu Zhou<sup>1</sup>

1 Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China, 2 Department of Pathology, Wuhan General Hospital of Guangzhou Command, People's Liberation Army, Wuhan, China, 3 Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China

Zhang Z-Y, Xu J, Ren Y, Yao Y, Li KK-W, et al. (2014) Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy. PLoS ONE 9(6): e99490. doi:10.1371/journal.pone.0099490

The email address for co-Corresponding Author Yu Yao is incorrect. The correct email address is: yu\_yao03@126.com.

Figure 2 is incorrect. The authors have provided a corrected version here.

**Citation:** The *PLOS ONE* Staff (2014) Correction: Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy. PLoS ONE 9(9): e107855. doi:10.1371/journal.pone.0107855

Published September 8, 2014

**Copyright:** © 2014 The *PLOS ONE* Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



**Figure 2. Univariate analysis of overall survival (OS) and event-free survival (EFS) of histological and molecular subgroups of medulloblastoma.** a-d: OS and EFS analysis in classic medulloblastoma (CMB, dark red) according to postoperative radiation therapy (RT) and chemotherapy (CHT). e-h: OS and EFS analysis in desmoplastic/nodular medulloblastoma (DMB, grey) according to postoperative RT and CHT. i-l: OS and EFS analysis in SHH medulloblastoma (red) according to postoperative RT and CHT. m-p: OS and EFS analysis in WNT medulloblastoma (green) according to postoperative RT and CHT. q-t: OS and EFS analysis in Non-SHH/WNT medulloblastoma (yellow) according to postoperative RT and CHT. Numbers on the Y axis indicate probability of survival in medulloblastoma patients. Numbers of the X axis indicate the follow-up time (months). doi:10.1371/journal.pone.0099490.g002

## Reference

 Zhang Z-Y, Xu J, Ren Y, Yao Y, Li KK-W, et al. (2014) Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy. PLoS ONE 9(6): e99490. doi:10.1371/journal.pone.0099490